The human brain has 100 billion neurons, connected to each other in networks that allow us to interpret the world around us, plan for the future, and control our actions and movements. MIT neuroscientist Sebastian Seung wants to map those networks, creating a wiring diagram of the brain that could help scientists learn how we each become our unique selves.
The field of Tissue Engineering, an interdisciplinary field focused on building or regenerating functional three-dimensional tissues, has deployed several fabrication strategies aimed at bringing cells and structure together to generate tissue.
In a complex sequence of spin-offs, name-changes and mergers, the dust has settled for vision correction company GlassesOff, formerly called Autovative Products and recently restructured through a merger with software company Ucansi. The former Autovative Products also created a spin-off, Autovative Technologies, which will be headed by former CEO David Funderburk.
Ocular Therapeutix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has scheduled an Ophthalmic Devices Panel meeting on September 19, 2013 to discuss, make recommendations, and vote on the company’s Premarket Approval (PMA) Application for the ReSure Sealant.
A new transparent, bioinspired coating makes ordinary glass tough, self-cleaning and incredibly slippery, a team from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard School of Engineering and Applied Sciences (SEAS) reported online in the July 31 edition of Nature Communications.
An FDA advisory panel is slated to convene Sept. 19 to review the pre-market approval application for Ocular Therapeutix Inc.'s ReSure sealant. The FDA's Ophthalmic Devices Panel will review the PMA for the ReSure product, a hydrogel designed to seal incisions to the cornea made during cataract or intraocular lens placement surgery.
Orthokeratology, also known as corneal refractive therapy, has re-emerged as a treatment for near and far-sightedness, but while the technology provides an intermediate solution between existing interventions, its high price tag will hinder its adoption in the corrective vision market, according to an analyst with research and consulting firm GlobalData.
A smartphone app that keeps track of your location and distance walked from home or hotel and warns you when you are likely to be caught out after dark has been developed by researchers in Pakistan to help sufferers of the debilitating disease night blindness.
EP Global Communications, Inc. and EPGL Medical announced today that Company engineers have invented the world's first self powered, self contained, power source for contact lenses. The power supply comes from within the lenses and is self perpetuating day or night.
ReVision Optics said it's raised $55 million from a consortium of investors and closed enrollment in a clinical trial of its Raindrop near vision inlay to treat presbyopia. The Lake Forest, Calif.-based company said all of its existing backers – Canaan Partners, ProQuest Investments, InterWest Partners and Domain Assoc. – were joined by new investors Johnson & Johnson Development Corp. and RusnanoMedInvest in the round.
Second Sight Medical is hoping to raise $10.5 million, according to a regulatory filing, as it brings its "bionic eye" Argus II retinal implant to the U.S. market. The device, comprised of an eyeglass-mounted camera and an electrical stimulator implanted in the eye, works by converting video images captured by a miniature camera housed in the patient's glasses...
No computer works as efficiently as the human brain – so much so that building an artificial brain is the goal of many scientists. Neuroinformatics researchers from the University of Zurich and ETH Zurich have now made a breakthrough in this direction by understanding how to configure so-called neuromorphic chips to imitate the brain's information processing abilities in real-time.
Abbott Laboratories announced Monday it would pay a combined $560 million to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery. The acquisitions of Idev Technologies and OptiMedica Corp will help the health care company expand its medical device offerings.
Abbott has announced it has entered into an agreement to purchase OptiMedica Corporation, a privately held, Silicon Valley-based ophthalmic device company. The acquisition will enable Abbott to expand its vision care business into the femtosecond laser-assisted cataract surgery market.
A research group at the University of Alicante has developed an application for smart phones designed for the blind to overcome aerial obstacles such as branches or awnings, which cannot be done with guide dogs or walking sticks. This software has been awarded a prize by the Vodafone Foundation.
On this episode of The Pulse, a device that helps train the brain to turn sounds into images, detecting cancer by imaging the consumption of sugar, biomedical applications for a new hydrogel, and a nanofiber mesh that treats tumors with both thermotherapy and chemotherapy.
Retina Implant AG has announced that its wireless subretinal implant technology, the Alpha IMS, has received CE Mark. Retina Implant's technology, which has been in clinical trials across the world since 2005, is designed to restore useful vision in patients blinded by the degenerative eye condition retinitis pigmentosa.
The vOICe sensory substitution device is a revolutionary tool that helps blind people to use sounds to build an image in their minds of the things around them. A research team, led by Dr Michael Proulx, from the University's Department of Psychology, looked at how blindfolded sighted participants responded to an eye test using the device.
European healthcare regulators this month granted CE Mark approval to Retina Implant AG's Alpha IMS, a tiny eye implant that restores "useful" vision in patients blinded by retinitis pigmentosa. Reutlingen, Germany-based Retina Implant AG, founded in 2003 from a German research institute spinout, touts the technology as "artificial sight."
Germany’s Retina Implant developed the device, called Alpha IMS, which features a light-sensitive three-millimeter square microchip that detects images with photodiodes and communicates the information electrically to nerve cells in the retina.
Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa, today announced that its wireless subretinal implant technology, the Alpha IMS, has received CE Mark. Retina Implant's technology, which has been in clinical trials across the world since 2005, is designed to restore useful vision in patients blinded by the degenerative eye condition retinitis pigmentosa.
As more therapies are able to indicate implantable devices for treatment, incorporating drug delivery into them can be a significant additional benefit. Even when drug delivery is the primary function, implantable devices can be preferable. This article reviews some representative applications that device designers can leverage in developing new products for the implantable drug delivery market.
A team of researchers from the United States and Switzerland, led by University of California San Diego Professor Joseph Ford, has created a slim, telescopic contact lens that can switch between normal and magnified vision. With refinements, the system could offer AMD patients a relatively unobtrusive way to enhance their vision.
The antibacterial effects of silver are well established. Now, researchers at Yonsei University in Seoul, Republic of Korea, have developed a technique to coat glass with a layer of silver ions that can prevent growth of pathogenic bacteria including Escherichia coli, Salmonella typhimurium and Campylobacter jejuni. The technology could be used to protect medical equipment.
“Smart” eyewear has just collided with smart vision correction — and no, I’m not talking about the prescription-based versions of Google Glass that are in development. Researchers have taken the concept of Google Glass and applied it to soft contact lenses.